This is a working overview of WADA, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
== Conferences == There are several large conferences that are concerned with bioinformatics. Some of the most notable examples are European Conference on Computational Biology (ECCB), Intelligent Systems for Molecular Biology (ISMB), Pacific Symposium on Biocomputing (PSB), and Research in Computational Molecular Biology (RECOMB).
Joseph Abram, Le Havre: Modern City, 2011 Nathalie Castetz, Le Havre, Seine Estuary, Paris, Héliopoles, 2012, ISBN 978-2-919006-10-6 Franck Godard and Olivier Bouteiller, Le Havre, Déclics, 2011, ISBN 978-2-84768-231-1 Unusual Le Havre, Renée Grimaud, Les beaux jours, 2012, ISBN 978-2-35179-101-1 Jean-François Massé, Le Havre, attached port, Acanthe, 2003, ISBN 2-84942-003-4 Tristan Gaston-Breton, Le Havre 1802–2002: Two centuries of economic adventure, Le Cherche midi, 2002, ISBN 2-7491-0028-3 E. Simon, A. Fiszlewicz, Le Havre: What an Estuary!, Petit à Petit, 2002, ISBN 2-914401-26-4 Madeleine Brocard, Atlas of the Estuary of the Seine, Rouen, Presses de l'université de Rouen, 1996 Emanuelle Real, The Industrial Landscape of Basse-Seine, Connaissance du patrimoine en Haute-Normandie, 2009, ISBN 2-910316-33-5, 264 pages Jacques Basile and Didier Guyot, Another Blue City, Editions Point de Vues, 2011, 120 pages, ISBN 978-2-915548-63-1
== Cancer == DPEP1 has been found to be highly expressed in colon tumor cells compared to normal colon cells—one study even found a ≥2 fold over-expression of DPEP1. Increased levels of DPEP1 have also been detected in colorectal cancer patients, suggesting that DPEP1 is a viable marker for disseminated colon tumor cells.
== History == Photoionization has a long history of use in mass spectrometry experiments, though mostly for research purposes and not for sensitive analytical applications. Pulsed lasers have been used for non-resonant multiphoton ionization (MPI), resonance-enhanced MPI (REMPI) using tunable wavelengths, and single-photon ionization using sum frequency generation in non-linear media (usually gas cells). Non-laser sources of photoionization include discharge lamps and synchrotron radiation. The former sources were not adaptable to high sensitivity analytical applications because of low spectral brightness in the former case and large "facility-size" in the latter case. Meanwhile, photoionization has been used for GC detection and as a source for ion mobility spectrometry for many years suggesting the potential for use in mass spectrometry. The first development of APPI for LC/MS was reported by Robb, Covey, and Bruins and by Syage, Evans, and Hanold in 2000. APPI sources were commercialized shortly thereafter by Syagen Technology and made available for most commercial MS systems and by Sciex for their line of MS instruments. Concurrent to the development of APPI was a similar use of a VUV source for low pressure photoionization (LPPI) by Syage and coworkers that accepted atmospheric pressure gas phase samples but stepped down the pressure for ionization to about 1 torr (~100 Pa) before further pressure reduction for introduction into a MS analyzer. This photoionization method is well suited as an interface between gas chromatography (GC) and MS.
Several critics complained about the required usage of the program Steam, the requirement to create an account, register the products, and permanently lock them to the account before being allowed to play, along with installation difficulties and lack of support.
Sources: en.wikipedia.org
Auxins are compounds that positively influence cell enlargement, bud formation, and root initiation. They also promote the production of other hormones and, in conjunction with cytokinins, control the growth of stems, roots, and fruits, and convert stems into flowers. Auxins were the first class of growth regulators discovered. A Dutch Biologist Frits Warmolt Went first described auxins. They affect cell elongation by altering cell wall plasticity. They stimulate cambium, a subtype of meristem cells, to divide, and in stems cause secondary xylem to differentiate. Auxins act to inhibit the growth of buds lower down the stems in a phenomenon known as apical dominance, and also to promote lateral and adventitious root development and growth. Leaf abscission is initiated by the growing point of a plant ceasing to produce auxins. Auxins in seeds regulate specific protein synthesis, as they develop within the flower after pollination, causing the flower to develop a fruit to contain the developing seeds. In large concentrations, auxins are often toxic to plants; they are most toxic to dicots and less so to monocots. Because of this property, synthetic auxin herbicides including 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) have been developed and used for weed control by defoliation. Auxins, especially 1-naphthaleneacetic acid (NAA) and indole-3-butyric acid (IBA), are also commonly applied to stimulate root growth when taking cuttings of plants. The most common auxin found in plants is indole-3-acetic acid (IAA).
Haber's new unit was called Pioneer Regiment 35. After brief training in Berlin, Hahn, together with physicists James Franck and Gustav Hertz, was sent to Flanders again to scout for a site for a first gas attack. He did not witness the attack because he and Franck were off selecting a position for the next attack. Transferred to Poland, at the Battle of Bolimów on 12 June 1915, they released a mixture of chlorine and phosgene gas. Some German troops were reluctant to advance when the gas started to blow back, so Hahn led them across No Man's land. He witnessed the death agonies of Russians they had poisoned, and unsuccessfully attempted to revive some with gas masks. On their next attempt on 7 July, the gas again blew back on German lines, and Hertz was poisoned. This assignment was interrupted by a mission at the front in Flanders and again in 1916 by a mission to Verdun to introduce shells filled with phosgene to the Western Front. Then once again he was hunting along both fronts for sites for gas attacks. In December 1916 he joined the new gas command unit at Imperial Headquarters. Between operations, Hahn returned to Berlin, where he was able to slip back to his old laboratory and work with Meitner, continuing with their research. In September 1917 he was one of three officers, disguised in Austrian uniforms, sent to the Isonzo front in Italy to find a suitable location for an attack, using newly developed rifled minenwerfers that simultaneously hurled hundreds of containers of poison gas onto enemy targets.
==== Nervous system ==== There are nerve cells, also known as neurons, present in the human body. They are branched out. These cells make up nervous tissue. A neuron consists of a cell body with a nucleus and cytoplasm, and cytoplasmic protrusions of an axon, and dendrites.
=== Laboratory tests === Laboratory tests are sometimes used to check for cachexia. Tests that are used include albumin, C-reactive protein, ghrelin, IGF-2, and leptin. Acute phase reactants (IL-6, IL-1b, tumor necrosis factor, IL-8, interferon gamma and serum cytokines are also studied but are not always reliable for predicting cachexia. Laboratory cut-off values are also not the same across different institutions. There is no single lab test that can confirm cachexia or predict whether it will develop.
Ooi and Skilling surmise that making wheels on this scale was a devotional practice particular to Dvaravati, since it is not found in other regions where Theravada was practised. The pairing of the wheel with deer, which stands for the Deer Park at Sarnath, developed in India and is seen in stone reliefs from south to north. It appears on the clay seals of the vihāra at Nālandā and on the sculptures of Phanagiri in Telangana, and it still stands on the roof-ridges of Tibetan monasteries. The four-lion capitals of Aśoka at Sarnath and Sanchi are thought to have carried dharmachakras as well. According to Harrison, the symbolism of "the wheel of the law" and the order of Nature is also visible in the Tibetan prayer wheels. The moving wheels symbolize the movement of cosmic order (ṛta).
Sources: en.wikipedia.org
Glycoproteins and phosphoproteins are usually associated with covalent bonds since they have a carbohydrate or phosphate residue attached to the side chains of certain amino acid residues like asparagine, serine, and threonine. On the other hand, metalloproteins usually involve coordination bonds where there would be bonds between the metal ions and side chains of some amino acids like histidine, cysteine, or aspartic acid. All of these interactions create stable structures that are important for protein function. It is common for the prosthetic group to contribute to the function of the protein. An example of this is if the prosthetic group is broken away from the protein, the function of that protein is lost. This is seen in hemoglobin. When the heme group of hemoglobin is removed, the function of the protein is lost, making it a nonfunctional protein. This all highlights the prosthetic groups importance in maintaining both the structure and protein activity of conjugated proteins.
== Toxicity == The biological function of TsPep2 is not clear yet, except from a small displacement on the 125I-KTX binding site on rat brain synaptosomes. However, it has been shown that this peptide is not toxic to mice. The LD50 of TsPep2 is currently unknown.
Epithelial tissue is composed of closely packed cells, bound to each other by cell adhesion molecules, with little intercellular space. Epithelial cells can be squamous (flat), cuboidal or columnar and rest on a basal lamina, the upper layer of the basement membrane, the lower layer is the reticular lamina lying next to the connective tissue in the extracellular matrix secreted by the epithelial cells. There are many different types of epithelium, modified to suit a particular function. In the respiratory tract there is a type of ciliated epithelial lining; in the small intestine there are microvilli on the epithelial lining and in the large intestine there are intestinal villi. Skin consists of an outer layer of keratinized stratified squamous epithelium that covers the exterior of the vertebrate body. Keratinocytes make up to 95% of the cells in the skin. The epithelial cells on the external surface of the body typically secrete an extracellular matrix in the form of a cuticle. In simple animals this may just be a coat of glycoproteins. In more advanced animals, many glands are formed of epithelial cells.
==== United States ==== In the United States, MDMA is listed in Schedule I of the Controlled Substances Act. In a 2011 federal court hearing, the American Civil Liberties Union successfully argued that the sentencing guideline for MDMA/ecstasy is based on outdated science, leading to excessive prison sentences. Other courts have upheld the sentencing guidelines. The United States District Court for the Eastern District of Tennessee explained its ruling by noting that "an individual federal district court judge simply cannot marshal resources akin to those available to the Commission for tackling the manifold issues involved with determining a proper drug equivalency."
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.